Genomictree Inc. (228760.KQ)

KRW 23550.0

(3.06%)

Long Term Debt Summary of Genomictree Inc.

  • Genomictree Inc.'s latest annual long term debt in 2023 was 97.51 Million KRW , up 15.23% from previous year.
  • Genomictree Inc.'s latest quarterly long term debt in 2024 Q2 was - KRW , down 0.0% from previous quarter.
  • Genomictree Inc. reported annual long term debt of 84.62 Million KRW in 2022, down -99.77% from previous year.
  • Genomictree Inc. reported annual long term debt of 37.27 Billion KRW in 2021, up 260.75% from previous year.
  • Genomictree Inc. reported quarterly long term debt of 87.56 Million KRW for 2024 Q1, down 0.0% from previous quarter.
  • Genomictree Inc. reported quarterly long term debt of 97.51 Million KRW for 2023 Q4, up 72.71% from previous quarter.

Annual Long Term Debt Chart of Genomictree Inc. (2023 - 2016)

Historical Annual Long Term Debt of Genomictree Inc. (2023 - 2016)

Year Long Term Debt Long Term Debt Growth
2023 97.51 Million KRW 15.23%
2022 84.62 Million KRW -99.77%
2021 37.27 Billion KRW 260.75%
2020 10.33 Billion KRW 760.96%
2019 1.2 Billion KRW 200.0%
2018 400 Million KRW 0.0%
2017 - KRW 0.0%
2016 - KRW 0.0%

Peer Long Term Debt Comparison of Genomictree Inc.

Name Long Term Debt Long Term Debt Difference
HLB Co., Ltd. 17.93 Billion KRW 99.456%
iNtRON Biotechnology, Inc. 258.29 Million KRW 62.246%
BINEX Co., Ltd. 5.57 Billion KRW 98.252%
Bioneer Corporation 12.5 Billion KRW 99.22%
Anterogen.Co.,Ltd. - KRW -Infinity%
MEDIPOST Co., Ltd. 6.99 Billion KRW 98.606%
CrystalGenomics, Inc. 29.88 Billion USD 99.674%
Helixmith Co., Ltd 151.68 Million KRW 35.71%
Chabiotech Co.,Ltd. 95.06 Billion KRW 99.897%
Medy-Tox Inc. 1.22 Billion KRW 92.045%
Peptron, Inc. 4.5 Billion KRW 97.833%
Amicogen, Inc. 70.65 Billion KRW 99.862%
Genexine, Inc. 22.68 Billion KRW 99.57%
HLB Therapeutics Co.,Ltd. 1.84 Billion KRW 94.701%
LegoChem Biosciences, Inc. 528.37 Million KRW 81.544%
ALTEOGEN Inc. 1.24 Billion KRW 92.194%
PharmaResearch Co., Ltd. 970.71 Million KRW 89.954%
SillaJen, Inc. 8.13 Billion KRW 98.801%
JETEMA, Co., Ltd. 60 Billion KRW 99.837%
OliX Pharmaceuticals,Inc 35.36 Billion KRW 99.724%
MedPacto, Inc. 1.68 Billion KRW 94.219%
D&D Pharmatech 5.12 Billion KRW 98.096%
EASY BIO,Inc. 30 Billion KRW 99.675%
GI Innovation, Inc. 2.9 Billion KRW 96.642%